83 related articles for article (PubMed ID: 3917966)
21. Endocrinological environment of polycystic ovarian disease.
Tanaka T; Fujimoto S
Horm Res; 1990; 33 Suppl 2():5-9. PubMed ID: 2128882
[TBL] [Abstract][Full Text] [Related]
22. Effects of dopamine and metoclopramide in polycystic ovary syndrome.
Barnes RB; Mileikowsky GN; Cha KY; Spencer CA; Lobo RA
J Clin Endocrinol Metab; 1986 Aug; 63(2):506-9. PubMed ID: 3722335
[TBL] [Abstract][Full Text] [Related]
23. Naloxone fails to increase LH levels in clomiphene treated men.
Foresta C; Scanelli G; Fabbri A; Gnessi L; Moretti C; Fraioli F
Horm Metab Res; 1984 Mar; 16(3):140-1. PubMed ID: 6425183
[TBL] [Abstract][Full Text] [Related]
24. Acute dopaminergic blockade augments the naloxone-induced LH rise in estrogen-treated postmenopausal women.
Parra A; Barrón J; Marín VA; Coutiño B; Belmont J; Coria I
Maturitas; 1997 May; 27(1):91-9. PubMed ID: 9158083
[TBL] [Abstract][Full Text] [Related]
25. The effects of ovariectomy and estrogen treatment on the dopamine inhibition of gonadotropin and prolactin release.
Judd SJ; Rigg LA; Yen SS
J Clin Endocrinol Metab; 1979 Aug; 49(2):182-4. PubMed ID: 572372
[TBL] [Abstract][Full Text] [Related]
26. Impairment of dopaminergic and opioidergic activity in patients with polycystic ovarian disease is restored by treatment for the induction of ovulation.
Nappi C; Petraglia F; Di Carlo C; De Rosa R; Zaccardo A; Genazzani AR; Montemagno U
Gynecol Obstet Invest; 1989; 27(1):38-41. PubMed ID: 2920972
[TBL] [Abstract][Full Text] [Related]
27. Effect of antagonists of dopamine and opiates on the basal and GnRH-induced secretion of luteinizing hormone, follicle stimulating hormone and prolactin during lactational amenorrhoea in breastfeeding women.
Tay CC; Glasier AF; McNeilly AS
Hum Reprod; 1993 Apr; 8(4):532-9. PubMed ID: 8501180
[TBL] [Abstract][Full Text] [Related]
28. Dopamine inhibits the naloxone induced gonadotrophin rise in man.
Delitala G; Devilla L; Di Biaso D
Clin Endocrinol (Oxf); 1980 Nov; 13(5):515-8. PubMed ID: 6784978
[TBL] [Abstract][Full Text] [Related]
29. Gonadotropin secretion in rats bearing a prolactin-secreting pituitary tumor: effects of naloxone administration.
Lamberts SW; Zuiderwijk JM; Bons EG; Uitterlinden P; de Jong FH
Fertil Steril; 1981 May; 35(5):557-62. PubMed ID: 6785115
[TBL] [Abstract][Full Text] [Related]
30. Dopamine might not be involved in the pathogenesis of polycystic ovary syndrome.
Ferriani RA; Silva de Sá MF; Moura MD; Moreira AC; Gomes UA
Gynecol Endocrinol; 1989 Dec; 3(4):317-27. PubMed ID: 2516707
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of luteinizing hormone release by dopamine infusion in healthy women and in various pathophysiological conditions.
Ferrari C; Rampini P; Malinverni A; Scarduelli C; Benco R; Caldara R; Barbieri C; Testori G; Crosignani PG
Acta Endocrinol (Copenh); 1981 Aug; 97(4):436-40. PubMed ID: 6791426
[TBL] [Abstract][Full Text] [Related]
32. Effect of different doses of naloxone on serum levels of prolactin and gonadotropins in young male volunteers.
Knuth UA; Nieschlag E
J Endocrinol Invest; 1985 Feb; 8(1):55-7. PubMed ID: 3921597
[TBL] [Abstract][Full Text] [Related]
33. On the role of dopamine receptors in the naloxone-induced hormonal changes in man.
Delitala G; Devilla L; Musso NR
J Clin Endocrinol Metab; 1983 Jan; 56(1):181-4. PubMed ID: 6847869
[TBL] [Abstract][Full Text] [Related]
34. Naloxone administration does not affect gonadotropin secretion in agonadal men either basally or during testosterone treatment.
De Feo ML; Maggi M; Guardabasso V; Rodbard D; Delitala G; Fazzi V; Genazzani AD; Facchinetti F; Forti G
J Clin Endocrinol Metab; 1986 Jul; 63(1):257-61. PubMed ID: 3086359
[TBL] [Abstract][Full Text] [Related]
35. Effect of narcotic analgesics and naloxone on proestrous surges of LH, FSH and prolactin in rats.
Muraki T; Nakadate H; Tokunaga Y; Kato R; Makino T
Neuroendocrinology; 1979; 28(4):241-7. PubMed ID: 35761
[TBL] [Abstract][Full Text] [Related]
36. Increased dopamine turnover in women with polycystic ovary syndrome.
Segos C; Markianos M; Aravantinos D
Eur J Obstet Gynecol Reprod Biol; 1989 Dec; 33(3):229-34. PubMed ID: 2513236
[TBL] [Abstract][Full Text] [Related]
37. The dopaminergic inhibition of LH secretion during the menstrual cycle.
Ropert JF; Quigley ME; Yen SS
Life Sci; 1984 May; 34(21):2067-73. PubMed ID: 6427547
[TBL] [Abstract][Full Text] [Related]
38. Climacteric flushing: clinical and endocrine response to infusion of naloxone.
Lightman SL; Jacobs HS; Maguire AK; McGarrick G; Jeffcoate SL
Br J Obstet Gynaecol; 1981 Sep; 88(9):919-24. PubMed ID: 6791684
[TBL] [Abstract][Full Text] [Related]
39. The effects of naloxone on hot flashes and gonadotropin secretion in postmenopausal women.
DeFazio J; Verheugen C; Chetkowski R; Nass T; Judd HL; Meldrum DR
J Clin Endocrinol Metab; 1984 Mar; 58(3):578-81. PubMed ID: 6420445
[TBL] [Abstract][Full Text] [Related]
40. Can women with gonadotropin levels diagnostic of polycystic ovarian syndrome benefit from therapy with dopamine agonists?
Harrison RF; Synnott M; O'Moore R; O'Moore M
Ann N Y Acad Sci; 1993 May; 687():272-9. PubMed ID: 8100697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
